The historical rank and industry rank for AIM ImmunoTech's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, AIM ImmunoTech's highest Price to Tangible Book Ratio was 41.73. The lowest was 0.39. And the median was 1.63.
AIM's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.88 * Ranked among companies with meaningful Price-to-Tangible-Book only.
AIM ImmunoTech Price-to-Tangible-Book Historical Data
The historical data trend for AIM ImmunoTech's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AIM ImmunoTech's Price-to-Tangible-Book
For the Biotechnology subindustry, AIM ImmunoTech's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
AIM ImmunoTech Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of AIM ImmunoTech's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AIM has been successfully added to your 